NEW YORK – Personal Genome Diagnostics said Tuesday that it has partnered with the Center for Immunotherapy and Precision Immuno-Oncology and the Cleveland Clinic Lerner Research Institute, with plans to enhance PGDx's Elio plasma complete test reports and develop new liquid biopsy methods and assay iterations.
The effort is being led by Jame Abraham, interim chair of the Cleveland Clinic Taussig Cancer Institute, and Brian Rubin, chairman of the clinic's Pathology and Laboratory Medicine Institute.
In a statement, Timothy Chan, chair of Cleveland Clinic’s Center for Immunotherapy and Precision Immuno-Oncology, said the collaboration will allow the institutes to explore new options to improve treatment strategies and patient outcomes in cancer.
"By investing in comprehensive testing solutions that utilize noninvasive sampling techniques, we intend to explore the clinical utility of high impact biomarkers such as blood TMB, clonal hematopoiesis, and others, with the aim to improve therapeutic modalities for human cancers," he said.
"We look forward to expanding upon the capabilities of Elio plasma complete and paving the way for a center of excellence enabling enhanced testing of ctDNA in cancer," PGDx CEO Megan Bailey added.